NEW YORK – Guardant Health said Thursday that it has entered into an agreement with Bayshore HealthCare, a Canadian home and community healthcare service provider, to offer Guardant's portfolio of precision oncology tests through its network of clinics in Canada.
Bayshore provides care to over 350,000 Canadians every year. Under the new agreement, its clinics will now offer patients Guardant's tests, which include Guardant360, a genomic profiling test to guide therapy selection in advanced cancer, Guardant Reveal, a blood test for minimal residual disease detection and recurrence monitoring in early-stage cancer, and the company's Shield blood test for colorectal cancer screening.
Financial terms of the agreement were not disclosed.